Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | PDE8A | O60658 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306090 | 0.90 | NSD2 (0.46) | TLR7NSD2NSD3YTHDC1PDE4A | |
| SCHEMBL2058782 | 0.89 | YTHDC1 (0.55) | TLR7NUDT1YTHDC1PDE4APDE4B | |
| SCHEMBL15315258 | 0.88 | YTHDC1 (0.46) | TLR7YTHDC1CTSL | |
| SCHEMBL21449005 | 0.88 | TLR7 (0.47) | TLR7NSD2NSD3YTHDC1PDE4A | |
| SCHEMBL16481581 | 0.87 | TLR7 (0.52) | TLR7NUDT1PDE4APDE4BPDE4C | |
| SCHEMBL17154082 | 0.87 | TLR7 (0.52) | TLR7NUDT1YTHDC1PDE4APDE4B | |
| SCHEMBL12305226 | 0.86 | TLR7 (0.47) | TLR7NSD2NSD3NUDT1YTHDC1 | |
| SCHEMBL7206653 | 0.86 | TLR7 (0.51) | TLR7NUDT1PDE4APDE4BPDE4C | |
| SCHEMBL509407 | 0.85 | TLR7 (0.64) | TLR7NUDT1YTHDC1PDE4APDE4B | |
| SCHEMBL12305232 | 0.85 | TLR7 (0.46) | TLR7NUDT1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-08-08 | — | — | US | disclosed |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-07-25 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| WO-2024092067-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-07-15 | — | — | US | disclosed |
| US-10030066-B2 | Immune receptor modifier conjugate and preparation method and use thereof, coupling precursor for preparing same, and compound for synthesizing coupling precursor | SHENZHEN UNIVERSITY (CN) | 2018-07-24 | — | — | US | disclosed |
| US-10030066-B2 | Immune receptor modifier conjugate and preparation method and use thereof, coupling precursor for preparing same, and compound for synthesizing coupling precursor | SHENZHEN UNIVERSITY (CN) | 2018-07-24 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| WO-2011134669-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134668-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2125007-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | Regents of the University of California (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | CD4, IL4, CCR4 | TLR7 20/4885NSD2 2774/4885NSD3 866/4885 |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | TLR7 3594/4885NSD2 2070/4885NSD3 1097/4885 |
| US-20090324551-A1 | TLR AGONISTS | TLR3, TLR1, TLR5 | TLR7 6/4885NSD2 3649/4885NSD3 3122/4885 |
| US-10030066-B2 | Immune receptor modifier conjugate and preparation method and use thereof, coupling precursor for preparing same, and compound for synthesizing coupling precursor | ADAR, AGER, HAVCR2 | TLR7 22/4885NSD2 4322/4885NSD3 4389/4885 |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NSD2 3791/4885NSD3 2675/4885 |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | TLR7, TLR9, TLR8 | TLR7 1/4885NSD2 3038/4885NSD3 3055/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NSD2 3791/4885NSD3 2675/4885 |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NSD2 3791/4885NSD3 2675/4885 |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NSD2 3791/4885NSD3 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.